BiotechTube
Alderley Analytical

Alderley Analytical

Cheshire, United Kingdom· Est.
alderleyanalytical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2008 and operational from 2014, Alderley Analytical is a private, revenue-generating CRO offering specialized bioanalytical services to pharmaceutical, biotech, and other CRO clients. The company leverages a dual-technology platform centered on state-of-the-art LC-MS/MS and ligand binding assays (including ECLIA via MSD), supported by a full GLP/GCP-accredited quality system and a Watson LIMS. With a seasoned founding team, a history of angel and venture investment, and a profitable track record since 2017, Alderley Analytical is positioned as a flexible, communicative partner in the outsourced bioanalysis market, though it faces risks from client concentration and technological obsolescence.

DiagnosticsProteomics

Technology Platform

Integrated bioanalytical platform utilizing Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) for small molecules, peptides, and oligonucleotides, and Ligand Binding Assays (including ELISA and Electrochemiluminescence (ECLIA) via Meso Scale Discovery) for large molecules, biomarkers, and immunogenicity testing. Supported by a GLP/GCP quality system, Watson LIMS, and 24/7 environmental monitoring.

Opportunities

Growth in complex modalities like oligonucleotides, peptides, and biologics drives demand for specialized bioanalytical expertise.
The trend among small and mid-sized biotechs to outsource to a single, long-term CRO partner aligns perfectly with the company's core value proposition.
Expansion of immunogenicity and biomarker service offerings presents a direct path to capture more value from existing client projects.

Risk Factors

Revenue is vulnerable to cyclicality in biotech R&D funding and client project timelines.
The capital-intensive need to continuously update analytical technology poses a financial and competitive risk.
Maintaining flawless regulatory compliance is critical; any inspection failure could severely damage the company's reputation and commercial prospects.

Competitive Landscape

Alderley Analytical competes in a fragmented but competitive bioanalytical CRO market against large global full-service CROs (e.g., LabCorp, IQVIA) and numerous niche specialist labs. Its differentiation lies in its UK-based regulatory accreditation, focused expertise on a range of molecule types, and emphasis on being a dedicated, communicative partner rather than a transactional vendor.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →